Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as has completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
Latest shares articles
GBP/USD attempts recovery as UK CPI rises once again
UK inflation rose unexpectedly in June, moving further away from the Bank of England's 2% and limiting the amount of future rate cuts
08:25, 16 July 2025
EUR/USD: bullish narrative tested by U.S. trade threats
US tariff threats weigh on euro sentiment as the dollar regains the upper hand
07:47, 15 July 2025
US CPI Preview: Inflation data to test Fed’s tariff assumptions and policy expectations
US CPI data could impact the Fed's views on tariffs, inflation and monetary policy
18:52, 14 July 2025
Cocoa price prediction: Third-party target
Read our cocoa price forecast for 2025 and beyond, with insights from third-party analysts and commodities market experts.
15:59, 14 July 2025
Ratings and Reviews
Ratings and Reviews
